RNAZ News

After a record breaking number of deals last week, the IPO market cooled off for the shortened holiday week, with just two micro-cap IPOs raising $45 million.  Preclinical RNA biotech Transcode Therapeutics (RNAZ) priced at $4 to raise $25 million at a $54 million market cap. This oncology biotech develops RNA therapeutics for the treatment of solid...read more

Transcode Therapeutics, a preclinical biotech developing RNA-based targeted therapies for cancer, raised $25 million by offering 6.25 million shares at $4.00. At $4.00, TransCode Therapeutics commands a fully diluted market value of $54 million. The company originally filed to offer 2.8 million shares at a range of $8 to $10, before cutting the proposed offer price to $4 at the...read more

Transcode Therapeutics, a preclinical biotech developing RNA-based targeted therapies for cancer, amended the terms for its upcoming IPO on Monday. The Boston, MA-based company now plans to raise $25 million by offering 6.3 million shares at $4. The company previously filed to raise $25 million by offering 2.8 million shares at a range of $8 to $10. At the revised terms,...read more

Transcode Therapeutics, a preclinical biotech developing RNA-based targeted therapies for cancer, announced terms for its IPO on Wednesday. The Boston, MA-based company plans to raise $25 million by offering 2.8 million shares at a price range of $8 to $10. At the midpoint of the proposed range, Transcode Therapeutics would command a fully diluted market value of $92 million. ...read more